Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

2.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

3.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

4.

New imaging guidelines for head and neck cancers, a step toward practice change

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot